VS

Vimal Swaroop

Director Director DIN 08678112
DIN 08678112 First appointment Jan 2020 Primary industry Pharma
Unlock full profile Investments · shareholding · contact details
Past companies 2 historical roles
Total affiliations 2 Since Jan 2020
Shareholding value •••• Premium profile

About Vimal Swaroop

Data last updated:

Vimal Swaroop was a Director at Ericca Pharmaceutical Private Limited (2020–2025) and Director at Siya Pharmaceutical Private Limited (2023–2024). The companies operate in Pharma.

DIN 08678112
Primary Designation Director
Industry Pharma
First Appointment 24 Jan 2020

Previous companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director24 Jan 20202020Active
Siya Pharmaceutical Private Limited U46497MH2023PTC412251
Director16 Oct 20232023Active

Explore Director's current and past company associations Uncover their professional journey today!

Directorship timeline

Open interactive timeline →
Ericca Pharmaceutical Private Limited
Siya Pharmaceutical Private Limited
Premium access

Shareholding and investment profile for Vimal Swaroop

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Vimal Swaroop

Vimal Swaroop was first appointed on 24 Jan 2020 as Director at Ericca Pharmaceutical Private Limited. The most recent appointment on record is 16 Oct 2023 at Siya Pharmaceutical Private Limited.

Vimal Swaroop held 2 earlier board appointments: Ericca Pharmaceutical Private Limited (Director, 24 Jan 2020 to 07 Jun 2025); Siya Pharmaceutical Private Limited (Director, 16 Oct 2023 to 12 Mar 2024).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available